Colleen Erb, MSN, ACNP-BC, AOCNP, from Fox Chase Cancer Center writes about the debilitating effects of cancer treatments for patients – specifically peripheral neuropathy. Her article is in-depth and loaded with information. READ MORE Source: OncologyNurseAdvisor.com
The diabetes drug rosiglitazone (Avandia) is now being explored as a pain medication. The drug was initially controversial with some experts wanting to banish it and others wanting very tight restrictions. In a study that will be published in Anesthesia and Analgesia, a team from Juntendo University School of Medicine in Tokyo, Japan, has some new …
A new study published by Pamlab, LLC, in the Review of Neurological Diseases measured epidermal nerve fiber density (ENFD) after using a nutritional management product, Metanx. Dispensed by prescription, the medical food offers a nutritional benefit by improving and maintaining blood flow in the vessels that carry important nutrients and oxygen to the peripheral nerves. READ MORE …
Increased Nerve Fiber Density after Dietary Management with a Medical Food Read More »
Lpath announced on August 15 the Type 1 Diabetes Preclinical Testing Program of the NIH will provide support for the further study of Lpathomab’s efficacy in animal models of disease, particularly diabetic neuropathy. Lpathomab functions like a ‘molecular sponge’ that binds to, and neutralizes, the bioactive lipid signaling molecule, thus silencing receptors associated with the …
Lpath Addresses Diabetic Neuropathic Pain with Financial Support by NIH Read More »
A recent study published in Diabetes Care highlighted the importance of R-Alpha Lipoic for the diets of diabetics. Nutri-Med Logic also reported that according to Current Diabetes Report, there is a valid relationship between nutritional supplementation of R-Alpha Lipoic and health benefits in type 2 diabetes. READ MORE Source: DiabetesCare
In a program designed to facilitate the development and expedite the review of new drugs, the FDA created the Fast Track program. DARA BioSciences has been awarded the Fast Track designation for their KRN5500 investigational drug which will be used for the treatment of neuropathic pain in cancer patients. DARA earlier reported positive results from …
A study published in the Annals of Neurology indicates that a single gene may be responsible for the pain suffered in many people with a type of peripheral neuropathy that previously had no known cause. The discovery could lead to effective treatments for the disorder. Â READ MORE Source: Web MD
For the 20 million Americans suffering with PN, there is no good treatment for the disorder and doctors can find no apparent cause in one of every three cases. An international team of scientists have found that mutations of a single gene are linked to 30 percent of cases of unexplained neuropathy. The findings, published …
Blood vessels and supporting cells appear to be pivotal partners in repairing nerves ravagedby diabetic neuropathy, and nurturing their partnership with nerve cells might make the difference between success and failure in experimental efforts to regrow damaged nerves, Johns Hopkins researchers report in a new study. Current treatments focus on relieving symptoms but don’t address …
In a study conducted by Dr. Sugato Banerjee of the HIV Neurobehavioral Research Center in San Diego and his colleagues a potential connection has been found between elevated lipid levels and neuropathy in people receiving antiretroviral treatments. Managing the elevated triglyceride levels may reduce the risk of developing this debilitating nerve condition. Â READ MORE Source: …
High Triglycerides Increase Risk of Neuropathy for Patients with HIV Read More »
